Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS??? EQUITY

v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Total Stockholders' Equity
Non-controlling Interests
Beginning balance (in shares) at Jan. 01, 2023   157,461,802          
Beginning balance at Jan. 01, 2023 $ 356,427 $ 15 $ 741,186   $ (384,774)    
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net loss (73,603)       (73,603)    
Issuance of common stock upon exercise of stock options (in shares)   86,654          
Issuance of common stock upon exercise of stock options 328   328        
RSUs vested, net of shares withheld (in shares)   679,606          
RSU vested, net of shares withheld (777)   (777)     $ (777)  
Vesting of early exercised stock options 83 $ 1 82     83  
Repurchase of unvested restricted common stock (in shares)   (138,599)          
Stock-based compensation 29,653   29,653        
Other comprehensive income, net 0            
Ending balance (in shares) at Apr. 02, 2023   158,089,463          
Ending balance at Apr. 02, 2023 $ 312,111 $ 16 770,472 $ 0 (458,377) 312,111 $ 0
Beginning balance (in shares) at Dec. 31, 2023 167,392,315 167,392,315          
Beginning balance at Dec. 31, 2023 $ 261,103 $ 17 857,037 (62) (598,845) 258,147 2,956
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net loss $ (46,497)       (46,368) (46,368) (129)
Issuance of common stock upon exercise of stock options (in shares) 43,041 43,041          
Issuance of common stock upon exercise of stock options $ 96   96     96  
Issuance of common stock, net of issuance costs (in shares)   639,138          
Issuance of common stock, net of issuance costs 5,756   5,756     5,756  
RSUs vested, net of shares withheld (in shares)   1,683,618          
RSU vested, net of shares withheld (2,223)   (2,223)     (2,223)  
Vesting of early exercised stock options 9   9     9  
Repurchase of unvested restricted common stock (in shares)   (19,638)          
Stock-based compensation 13,852   13,852     13,852  
Other comprehensive income, net $ 9     9   9  
Ending balance (in shares) at Mar. 31, 2024 169,738,474 169,738,474          
Ending balance at Mar. 31, 2024 $ 232,105 $ 17 $ 874,527 $ (53) $ (645,213) $ 229,278 $ 2,827